Sham-Controlled HF-dTMS Trial Tests Triglyceride Baseline

A randomized sham-controlled trial of high-frequency deep repetitive transcranial magnetic stimulation (HF-dTMS) has posted ahead of print in Clinical EEG and Neuroscience, with fasting triglyceride (TG) levels checked as a candidate predictor of treatment response in major depressive disorder.

The protocol carries two stated objectives up front: assess the efficacy and safety of HF-dTMS, then explore whether baseline TG stratifies responders from non-responders. Both questions have surfaced in adjacent rTMS literature. Bundling them inside one sham-controlled design is the move worth attention.

What does the design change for the evidence base?

Sham control is the hinge.

HF-dTMS coils reach deeper limbic targets than figure-of-eight setups. Open-label case series still dominate the deep-coil record, which leaves placebo effects harder to dismiss at the cohort level.

A blinded design here applies the discipline that earlier pivotal work applied to conventional rTMS — only later than practicing neurostimulation clinicians would like. Once published in full, the trial's primary efficacy contrast will carry the same evidentiary weight conventional rTMS sham data carry now, scaled to a deeper-coil device class.

Why triglycerides, and why should practitioners care?

A lipid panel is already routine. Most psychiatric intakes include fasting lipids as part of cardiovascular screening.

If baseline TG forecasts HF-dTMS response, clinics flag likely responders before the first coil lands and steer poor-probability patients toward alternatives before consent forms are signed. That reorders the pre-stimulation conversation.

Exclusion criteria currently dominate the pre-TMS checklist: metal implants, seizure history, pregnancy, certain medications. A positive TG result would not replace any of them. It would add a probability layer grounded in a routine blood draw, the kind already filed in the chart.

What does the source show, and what does it withhold?

The ahead-of-print posting surfaces the trial's stated objectives and the methods opening. Sample size per arm, stimulation intensity as a percent of resting motor threshold, total pulses per session, session count, exact TG thresholds evaluated, and primary endpoint scoring all sit outside the publicly visible excerpt.

Ahead-of-print posting typically leads with objectives first, full results after peer review finalizes. Treat the early version as design scaffolding, not a results sheet. The numerical answer ships with the peer-reviewed version.

How would a TMS clinic read this?

If the TG secondary objective lands, fasting lipid becomes a triage variable usable in any clinic with a centrifuge. Cheaper than imaging. Faster than genetic panels. A single blood draw sets the counseling frame; every downstream session calibrates against that baseline.

A negative finding carries its own value. It clears a candidate marker practitioners have quietly hoped might work, and pushes stratification effort toward imaging, polygenic, or EEG-based predictors already in development across the brain-stimulation field.

For neurophysiology readers outside TMS practice, the protocol signals a wider shift. Brain-stimulation biomarkers increasingly lean on cheap, population-scale variables rather than bespoke scanners. Routine lab values now replace expensive stratification tools at the front end of trials.

What comes next?

Full results, once posted, will determine whether fasting TG enters the standard pre-rTMS checklist. Watch for the secondary-objective outcome and any effect-size threshold reported against patient-level TG values. Sham-controlled scaffolding is in place. What carries weight is what the published endpoints deliver.